Treatment with Lucemyra may lessen the severity of opioid withdrawal symptoms but it may not completely prevent them. We know that the physical symptoms of opioid withdrawal can be one of the biggest barriers for patients seeking help, and ultimately overcoming addiction. The most common adverse effects from treatment with lofexidine hydrochloride include low blood pressure, slow heart rate, sleepiness, sedation, and dizziness.
Most doctors are already using Clonidine in their treatment of opioid withdrawal, it is very inexpensive and has been around a long time. More patients in the Lucemyra group completed the treatment period of the studies vs patients in the placebo group. And those who seek assistance may relapse due to continued withdrawal symptoms. FDA approves the first non-opioid treatment for management of opioid withdrawal symptoms in adults [news release]: Silver Spring, MD; May 16, 2018.
The FDA granted the approval of Lucemyra to Louisville, Ky.-based pharmaceutical company US WorldMeds LLC, the agency said Wednesday. Lucemyra (lofexidine hydrochloride) was originally intended to be a hypertension drug. Comprehensive daily news report for those who discover, develop, and market drugs. Treatment protocols also include muscle relaxers, Trazadone for sleep, and Buprenorphine/Nalaxone or Naltrexone combos.
Through our print, digital and live events channels, Pharmacy Times ® provides clinically based, practical and timely information for the practicing pharmacist. Copyright © 2018 United Press International, Inc. The drug, which has been used in the United Kingdom for more than two decades now, is made by Louisville, KY-based US WorldMeds. It will be interesting to see whether a drug like Lucemyra competes or is used in tandem with drugs like Sublocade, the injectable version of Indivior’s popular opioid use disorder drug Suboxone.